NAFLD与MAFLD患者的临床特征及死亡结局差异
基于NHANES III中2997例超声诊断脂肪肝参与者,分为非MAFLD的NAFLD、NAFLD合并MAFLD、非NAFLD的MAFLD三组。非NAFLD的MAFLD组代谢异常更多、进展期纤维化比例更高(近8%),全因死亡累积发生率最高(26.2%),且与全因死亡独立相关(aHR 2.4)。
要点
- MAFLD标准可识别出合并症更多、预后更差的脂肪肝人群。
- 非NAFLD的MAFLD组进展期纤维化比例近8%,高于其他两组。
- 非NAFLD的MAFLD与全因死亡独立相关(aHR 2.4)。
核心结论
- MAFLD标准识别出合并症更多、预后更差的脂肪肝人群,应考虑在一般人群中用于识别高危群体以早期干预。
研究设计与样本
- 基于NHANES III 1988-1994数据,2997例超声诊断脂肪肝参与者分为非MAFLD的NAFLD、NAFLD合并MAFLD、非NAFLD的MAFLD三组。
主要发现
- NAFLD合并MAFLD组和非NAFLD的MAFLD组年龄更大、代谢特征更多、平均肝酶更高。
- 非NAFLD的MAFLD组近8%有进展期纤维化(Fibrosis-4指数>2.67),NAFLD合并MAFLD组为1.3%,非MAFLD的NAFLD组为1.9%(P < .0001)。
- 非NAFLD的MAFLD组全因死亡累积发生率最高(26.2%),其次为NAFLD合并MAFLD组(21.1%)和非MAFLD的NAFLD组(10.6%)(P < .0001)。
- 心血管疾病相关死亡和其他原因死亡也呈现类似趋势。
- 与非MAFLD的NAFLD相比,非NAFLD的MAFLD与全因死亡独立相关(调整后风险比2.4;95%CI 1.2-4.6;P = .01)。
关键数值与推荐
- 进展期纤维化定义为Fibrosis-4指数>2.67。
- 非NAFLD的MAFLD组进展期纤维化比例近8%,NAFLD合并MAFLD组1.3%,非MAFLD的NAFLD组1.9%(P < .0001)。
- 全因死亡累积发生率:非NAFLD的MAFLD组26.2%,NAFLD合并MAFLD组21.1%,非MAFLD的NAFLD组10.6%(P < .0001)。
- 非NAFLD的MAFLD vs 非MAFLD的NAFLD的全因死亡调整后风险比2.4(95%CI 1.2-4.6;P = .01)。
临床怎么用
- 在一般人群中可考虑采用MAFLD标准识别脂肪肝高危群体以进行早期干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Metabolic dysfunction-associated fatty liver disease (MAFLD) establishes new criteria for diagnosing fatty liver disease independent of alcohol intake and concomitant viral hepatitis infection. However, the long-term outcomes of patients with MAFLD are sparse. We aimed to describe the characteristics and long-term survival of persons meeting criteria for nonalcoholic fatty liver disease (NAFLD) only (non-MAFLD NAFLD), for both NAFLD and MAFLD (NAFLD-MAFLD), and for MAFLD only (non-NAFLD MAFLD). METHODS: Using data from the Third National Health and Nutrition Examination Survey (NHANES III) 1988-1994, 2997 participants with fatty liver identified via ultrasound were categorized into 3 distinct groups: non-MAFLD NAFLD, NAFLD-MAFLD, and non-NAFLD MAFLD. RESULTS: Participants in the NAFLD-MAFLD and non-NAFLD MAFLD groups were older, had more metabolic traits and higher mean liver enzymes. Nearly 8% of participants in the non-NAFLD MAFLD group had advanced fibrosis (Fibrosis-4 index >2.67), while only 1.3% and 1.9% in the NAFLD-MAFLD and non-MAFLD NAFLD groups did, respectively (P < .0001). Non-NAFLD MAFLD participants had the highest cumulative incidence of all-cause mortality (26.2%) followed by those with NAFLD-MAFLD then non-MAFLD NAFLD participants (21.1% and 10.6%, respectively; P < .0001). Similar findings were observed for cardiovascular disease-related and other-cause (noncardiovascular disease, noncancer) mortality. Non-NAFLD MAFLD was independently associated with all-cause mortality compared with non-MAFLD NAFLD (adjusted hazard ratio, 2.4; 95% confidence interval, 1.2-4.6; P = .01). CONCLUSIONS: MAFLD criteria identified a significant group of people with more comorbidities and worse prognosis compared with those with NAFLD only. These criteria should be considered in the general population to identify high-risk groups for early interventions.
引用
- Nguyen VH, Le MH, Cheung RC, et al. Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD. Clin Gastroenterol Hepatol. 2021. PMID: 34033923. doi:10.1016/j.cgh.2021.05.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。